The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer |
| |
| Authors: | Inoue Yoshimasa Tomisawa Masashi Yamazaki Hitoshi Abe Yoshiyuki Suemizu Hiroshi Tsukamoto Hideo Tomii Yasushi Kawamura Masafumi Kijima Hiroshi Hatanaka Hiroyuki Ueyama Yoshito Nakamura Masato Kobayashi Koichi |
| |
| Affiliation: | Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan. |
| |
| Abstract: | It is unclear whether a subunit of glutamate cysteine ligase [a modifier subunit (GCLM) and a catalytic subunit (GCLC)] is an effective target for ameliorating cisplatin (CDDP)-resistance. We inhibited each subunit of GCL mRNA using a specific ribozyme (M-Rz and C-Rz) in the pulmonary adenocarcinoma cell line A549. GCL activity was suppressed by the ribozyme. CDDP-resistance was more effectively ameliorated when GCLM rather than GCLC was inhibited. GCLM is a potentially more effective pharmacologic target for ameliorating CDDP-resistance in non-small cell lung cancer than GCLC. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
